Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30720088 | 0.98 | CASR (0.37) | PMP22CASRCA14ENPEPLMNA | |
| SCHEMBL6782700 | 0.83 | PMP22 (0.42) | PMP22CASRCA14CYP2C19LTA4H | |
| SCHEMBL629203 | 0.83 | PMP22 (0.42) | PMP22CASRCA14CYP2C19LTA4H | |
| SCHEMBL11776470 | 0.82 | SMN1; SMN2 (0.42) | CASRCA14LTA4HCA1CA2 | |
| SCHEMBL26627543 | 0.82 | CASR (0.37) | PMP22CASRCA14LTA4HCA12 | |
| SCHEMBL22268721 | 0.82 | CASR (0.37) | PMP22CASRCA14LTA4HCA12 | |
| SCHEMBL20528273 | 0.82 | TP53 (0.38) | PMP22ENPEPLMNASLC6A6CYP2C19 | |
| Hydrochloric Acid SCHEMBL8602951 | 0.82 | PMP22 (0.41) | PMP22CASRCA14CYP2C19LTA4H | |
| Hydrochloric Acid SCHEMBL8763031 | 0.82 | PMP22 (0.37) | PMP22CASRCA14LTA4HCA12 | |
| SCHEMBL1786590 | 0.81 | CA14 (0.39) | PMP22CASRCA14CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386947-B1 | METHOD FOR PRODUCING N-RETINOYLAMINOALKANE SULFONIC ACID | OASMIA PHARMACEUTICAL AB (SE) | 2021-05-19 | — | — | EP | disclosed |
| US-10322996-B2 | Method for producing N-retinoylcysteic acid alkyl ester | ARDENIA INVESTMENTS, LTD (GB) | 2019-06-18 | — | — | US | disclosed |
| US-20190127322-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | VIVESTO AB (SE) | 2019-05-02 | — | — | US | disclosed |
| US-10138204-B2 | Method for producing N-retinoylcysteic acid alkyl ester | ARDENIA INVESTMENTS, LTD (GB) | 2018-11-27 | — | — | US | disclosed |
| US-20180290973-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | VIVESTO AB (SE) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127322-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | AHCY, LRAT, RARA | PMP22 3079/4885CASR 1952/4885CA14 1260/4885 |
| US-20180290973-A1 | METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER | AHCY, LRAT, RARA | PMP22 3079/4885CASR 1952/4885CA14 1260/4885 |
| US-10138204-B2 | Method for producing N-retinoylcysteic acid alkyl ester | AHCY, LRAT, RARA | PMP22 3079/4885CASR 1952/4885CA14 1260/4885 |
| US-10322996-B2 | Method for producing N-retinoylcysteic acid alkyl ester | AHCY, LRAT, RARA | PMP22 3079/4885CASR 1952/4885CA14 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.